← Back to News Access & Economics

The real cost of MCAS — and why access matters

The bills people talk about are only part of the story. For MCAS, the largest costs are the ones that never show up on a single invoice — the years without a diagnosis, the trial-and-error, the lost work.

The hidden costs

Patients with MCAS often see many specialists over several years before getting answers. Each visit, test, and elimination trial adds up — in money, in time, and in the toll of living undiagnosed. Add lost income from unpredictable flares and the true cost dwarfs the price of any single device or app.

Why early patterns save money

Continuous monitoring changes the economics. When triggers and trends are visible early, the diagnostic path gets shorter, treatments get targeted faster, and expensive emergencies become rarer. Prevention and clarity are almost always cheaper than repeated crisis care.

Our non-profit approach

We're a non-profit on purpose. Any surplus goes back into research, patient assistance, and expanding access — never to shareholders. That means sliding-scale pricing and a patient-assistance program so that need, not income, decides who benefits.

Access isn't a feature. For a chronic illness, it's the difference between managing and suffering.

Working with insurers and providers

We're building partnerships with insurers, Medicaid and Medicare pathways, and provider networks so that coverage — not out-of-pocket cost — becomes the norm. The full picture lives on our Coverage page.

See how we're expanding coverage and access, read our non-profit promise, or learn about the MCT-1.